Navigation Links
Preclinical and Phase 1 Data of VTX-2337 Presented at 2013 ASCO Annual Meeting Shows Early Activity in Ovarian Cancer
Date:6/3/2013

SEATTLE, June 3, 2013 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. in collaboration with the Gynecologic Oncology Group and the National Cancer Institute's Cancer Therapy Evaluation Program announced today that positive preclinical and clinical data of VTX-2337 in combination with Doxil® (pegylated liposomal doxorubicin) or paclitaxel in women with recurrent ovarian cancer were presented at the American Society of Clinical Oncology (ASCO) annual meeting. Results indicate that the combination of VTX-2337 and chemotherapy is well tolerated with no evidence of synergistic toxicities. Encouraging signs of efficacy provided the rationale for the ongoing randomized, placebo controlled Phase 2 study of VTX-2337 in combination with pegylated liposomal doxorubicin in patients with recurrent or persistent ovarian cancer (GOG-3003, NCT01666444)

(Logo: http://photos.prnewswire.com/prnh/20120123/SF39404LOGO)

VTX-2337, a Toll-like Receptor 8 (TLR8) agonist, demonstrated a clear additive effect to Doxil in a humanized mouse model of ovarian cancer. Data demonstrated that this combination provides an enhanced effect in stimulating a variety of immune pathways associated with anti-tumor activity.

A Phase 1b trial conducted with the Gynecologic Oncology Group (GOG) in 13 patients with recurrent or persistent ovarian cancer demonstrated that the combination of VTX-2337 with Doxil is safe and well tolerated (GOG-9925, NCT01294293). The study reported no serious or unexpected drug-related adverse events and no evidence of synergistic toxicities. Eleven patients were evaluable for tumor response by RECIST 1.1. One patient achieved a complete response and 63 percent of patients had stable disease. A separate arm examining VTX-2337 with paclitaxel in 7 subjects showed similar tolerability with 43% stable disease.

"Given the absence of clear molecular drivers in high-grade serous ovarian cancer, targeting the tumor microenvironment with an immunotherapy like VTX-2337 is a good option for this difficult to treat patient population. The preclinical and early clinical data confirm the potential utility of igniting the patient's own immune system to help fight cancer," said Bradley Monk , M.D., St. Joseph's Hospital and Medical Center, chair of the Phase 1b and ongoing Phase 2 studies.

"We are excited to be working with the GOG to advance the clinical development of VTX-2337 in ovarian cancer," said Robert Hershberg , M.D., Ph.D., President and Chief Executive Officer of VentiRx Pharmaceuticals. "We see a strong scientific and clinical rationale for chemo-immunotherapy using our novel TLR8 agonist in this setting."

About VTX-2337
VTX-2337 is a Toll-like Receptor 8 (TLR8) agonist that directly activates multiple components of the innate immune system. This includes activation of human myeloid dendritic cells (mDCs), monocytes and natural killer (NK) cells resulting in the production of high levels of mediators known to orchestrate the integration of innate and adaptive anti-tumor responses.  

About The Gynecologic Oncology Group
The GOG is a national non-profit organization dedicated to clinical research in the field of gynecologic cancer. The purpose of the GOG is to improve the treatment of gynecologic cancer. These goals are addressed through research encompassing surgery, radiation therapy, chemotherapy, pathology, immunology and/or gynecologic nursing. To promote this mission, the GOG receives support from the National Cancer Institute (NCI) of the National Institutes for Health. The GOG has a history of establishing treatment standards for ovarian cancer, demonstrating improved survival with platinum therapy in the early 1980s and again with the combination of Taxol® and platinum in the mid-1990s.

About VentiRx Pharmaceuticals
VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases. The Company's lead product candidate is VTX-2337, a small molecule TLR8 agonist for the treatment of cancer. VentiRx has an exclusive, world-wide collaboration with Celgene Corporation. VentiRx is a privately held organization with operations in Seattle, Washington. For additional information, please visit www.ventirx.com.


'/>"/>
SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
2. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
3. Novocure Presents Preclinical Data at the American Association for Cancer Research (AACR)
4. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
5. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
6. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
7. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
8. N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
9. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
10. Plato BioPharma Presenting Preclinical capabilities at PKPD Summit Boston
11. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... May 24, 2016 Los ... terapia del mundo, introduce catéteres para la intervención ... OrbusNeich, una compañía global especializada en el suministro ... expandido su cartera incluyendo productos para tratar la ... Scoreflex™ PTA son los dispositivos de primera entrada ...
(Date:5/24/2016)... -- Dutch surgeons have launched a ground-breaking medical app ... treat patients on a global scale. Medical professionals from ... and the US have already signed up for the ... a totally secure environment. Education  "Imagine a ... with a surgeon at Harvard to treat a bomb victim via ...
Breaking Medicine Technology:
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... ... care products, has been honored with a 2016 When Work Works Award for its ... award, part of the national When Work Works project administered by the Families and ...
(Date:5/26/2016)... D.C. (PRWEB) , ... May 26, 2016 , ... On ... men and women who lost their lives in military battle for the country. ... cards in 2015 to provide more programs that empower independence for disabled military veterans, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced two key appointments and the ... investment and strategic growth plans in the Asia Pacific region. , Howard Kim ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of healthcare supply chain solutions, today announced the organization has earned its ISO ... international standards and is compliant with all rules and policies associated with ISO ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic surgeon ... officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an International ... May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on ...
Breaking Medicine News(10 mins):